Starting with low molecular weight fragments to explore drug molecules, it can efficiently cover the chemical space, and develop high-affinity drugs by optimizing the structure based on weakly binding fragments, with a high probability of discovering novel lead compounds.

It can rapidly and automatically detect a vast library of compounds, significantly shortening the drug screening cycle and quickly locking potential active compounds to accelerate the early process of drug development.

By using mass spectrometry technology, it can identify ligands of biomolecular targets without relying on the functional effects of ligands. It is suitable for complex mixtures and can efficiently screen and identify novel binding molecules.